A practical reference on research chemical: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-12-23. Anything still debated is marked as such rather than presented as settled.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small molecule; not a steroid or peptide. |
| Primary targets | NR1D1 and NR1D2 | Also known as REV-ERBα and REV-ERBβ. |
| Studied routes | Intraperitoneal in rodents | Oral bioavailability in humans is not established. |
| Human approval | No approved therapeutic indication | No recognized clinical use. |
| Key uncertainty | Human physiological effects | Preclinical findings may not translate. |
Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.
Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
==== 8 April ==== In Iran, the Lavan Oil Refinery, located on Lavan Island was struck at around 10 a.m.; a fire ignited. The Iranian authorities denounced the event and stated that it was an act of "cowardice" by the "enemies". Israel denied being involved in the attack. The debris of a drone shot down by Iranian forces killed a 7-year-old child and injured another six members of the child's family in the town of Shushtar in Khuzestan province.
== History == The RCMP carried out extensive security service work since the force was reconstituted in 1920, when it merged with the Dominion Police and became the federal police agency solely responsible for national security. Between the wars, this work was overwhelmingly directed at the Communist Party, as well as labour unions and Marxists more generally. It was in 1946 that the RCMP's Intelligence Section was put in charge of national security work. In 1950, the RCMP's Special Branch was formally established to conduct its counterintelligence operations. Prior to that, the branch was a component of the RCMP's Criminal Investigation Branch, where political security operations and criminal investigations were not distinct before 1936. The first Special Branch class was held in 1953. In 1962, the branch was renamed the Directorate of Security and Intelligence, and in 1970, it became the RCMP Security Service. During the 1960s, it targeted Quebec nationalists, particularly the militant Front de libération du Québec (FLQ).
The evidence for this stems from the different binding profiles of typical mu and delta agonists such as morphine and DAMGO respectively, in cells that coexpress both receptors compared to those in cells that express them individually. In addition, work by Fan and coworkers shows the restoration of the binding profiles when distal carboxyl termini are truncated at either receptor, suggesting that the termini play a role in the oligomerization. While this is exciting, rebuttal by the Javitch and coworkers suggest the idea of oligomerization may be overplayed. Relying on RET, Javitch and coworkers showed that RET signals were more characteristic of random proximity between receptors, rather than an actual bond formation between receptors, suggesting that discrepancies in binding profiles may be the result of downstream interactions, rather than novel effects due to oligomerization. Nevertheless, coexpression of receptors remains unique and potentially useful in the treatment of mood disorders and pain. Recent work indicates that exogenous ligands that activate the delta receptors mimic the phenomenon known as ischemic preconditioning. Experimentally, if short periods of transient ischemia are induced the downstream tissues are robustly protected if longer-duration interruption of the blood supply is then effected. Opiates and opioids with DOR activity mimic this effect. In the rat model, introduction of DOR ligands results in significant cardioprotection.
Sources: en.wikipedia.org
The combination of an estrogen and oral or vaginal progesterone has been found to improve cardiovascular health in women in early menopause but not in women in late menopause. Estrogen therapy has a favorable influence on the blood lipid profile, which may translate to improved cardiovascular health. The addition of oral or vaginal progesterone has neutral or beneficial effects on these changes. This is in contrast to various progestins, which are known to antagonize the beneficial effects of estrogens on blood lipids. Progesterone, both alone and in combination with an estrogen, has been found to have beneficial effects on skin and to slow the rate of skin aging in postmenopausal women. In the French E3N-EPIC observational study, the risk of diabetes was significantly lower in women on menopausal hormone therapy, including with the combination of an oral or transdermal estrogen and oral progesterone or a progestin.
These terminals are near the city center—along the Metro's Line 5 or near it—and connect to it via a metro line. Each station handles trains from different parts of Europe and Asia. Moscow contains many smaller railway stations. Because tickets are inexpensive, trains are Russians' preferred mode of travel, especially when traveling to Saint Petersburg. Moscow is the western terminus of the Trans-Siberian Railway, which crosses nearly 9,300 kilometers (5,800 mi) of Russian territory to reach Vladivostok on the Pacific coast. Suburbs and satellite cities are connected by a commuter elektrichka (electric rail) network. Elektrichkas depart from each of these terminals to the nearby large railway stations (up to 140 kilometers or 87 miles away). During the 2010s, the Little Ring of the Moscow Railway was converted for frequent passenger service. This ring is fully integrated with the Moscow Metro; passenger service started on 10 September 2016. A connecting railway line on the city's north side connects the Belorussky terminal with other railway lines. This line is used by some suburban trains.
== External links == The MEROPS online database for peptidases and their inhibitors: I39.001[link removed] alpha+2-Macroglobulin at the U.S. National Library of Medicine Medical Subject Headings (MeSH) A2M human gene location in the UCSC Genome Browser. A2M human gene details in the UCSC Genome Browser.
Sources: en.wikipedia.org
A diagnosis of BPD in adolescence can indicate the persistence of the disorder into adulthood, with outcomes varying among individuals. Some maintain a stable diagnosis over time, while others may not consistently meet the diagnostic criteria. Early diagnosis helps develop effective treatment plans, including family therapy, to support adolescents with BPD.
Enter on the credit side the receipt of 8,657.875 pesos paid by Manuel Mendes de Acuna, master of the ship San Juan Bautista, on 147 slave pieces brought by him into the said port on August 30, 1619, aboard the frigate Santa Ana, master Rodrigo Escobar. On the voyage inbound, Manuel Mendes de Acuna was robbed at sea off the coast of Campeche by English corsairs. Out of 350 slaves, large and small, he loaded in said Luanda the English corsairs left him with only 147, including 24 slave boys he was forced to sell in Jamaica, where he had to refresh, for he had many sick aboard, and many had already died.
Abiogenesis – Life arising from non-living matter Brine pool – Accumulation of brine in a seafloor depression Endeavour Hydrothermal Vents – Group of Pacific Ocean hydrothermal vents Extremophiles – Organisms capable of living in extreme environmentsPages displaying short descriptions of redirect targets Hydrogen sulfide chemosynthesis - system of generating energy used in hydrothermal vents Lost City Hydrothermal Field Magic Mountain (British Columbia) – Hydrothermal vent field in the northeast Pacific 9° North – Region of hydrothermal vents on the East Pacific Rise in the Pacific Ocean Pito Seamount – Seamount in the Pacific Ocean north-northwest of Easter Island Submarine volcano – Underwater vents or fissures in the Earth's surface from which magma can erupt Volcanogenic massive sulfide ore deposit, also known as VMS deposit – Metal sulfide ore deposit Deep sea mining
Sources: en.wikipedia.org
It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.
REV-ERB receptors generally repress transcription when bound by natural heme. SR9009 is described as an agonist that enhances this repressive activity. The result is altered expression of clock and metabolic genes.
Published controlled human trials are lacking. Some sources cite limited or unofficial reports, but these do not establish safety or efficacy. Claims about human performance effects remain unverified.
SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.